regimens. If the will to do a good job is there, and a good idea and infrastructure with supportive staff exist, it should be a relatively routine task for a group to organize and execute a drug trial. Problems are there, and the earlier WHO trials at Chingleput and Mali were not free from such problems. The majority of patients who attend Chingleput, JALMA, Karigiri, or other clinics have had dapsone monotherapy or various lengths of multidrug therapy previously, and everybody knows that any assertion on their part of having had no treatment is never taken seriously. That, of course, does not mean fresh cases do not arise or are not seen in clinics. But to get a number sufficiently large to be assigned to one or more treatment groups and a control group is next to impossible, unless one resorts to a modified life-table approach spread out over years. So, a controlled trial in a field situation with patients whose status of bias is considered and adjusted as much as is possible, seems to be the only possibility at this moment. And it is certainly possible to obtain results from such studies on which alternative treatment strategies can be based.

—Dr. B. R. Chatterjee

Leprosy Field Research Unit
The Leprosy Mission
P.O. Jhalda, Purulia
West Bengal 723202, India

Drs. Grosset and Ji’s Response to Dr. Chatterjee’s Comments

TO THE EDITOR:

The comments by Dr. Chatterjee regarding our Clinical Note entitled “Controlled clinical trial for evaluation of antimicrobial drug activity against M. leprae,” published in the June 1989 issue of the JOURNAL (1), are most welcome. However, we feel that his comments reflect more misunderstanding than disagreement.

For example, we agree entirely with Dr. Chatterjee that incompatibility of drugs in a combination is a possible cause of treatment failure. For this reason, we emphasized that treatment failure may be attributed to “poor antimicrobial activity of the drug(s)” and that evidence of the antimicrobial activity should be firmly established before undertaking a clinical trial.

We also agree that the immune responses of the host play an important role throughout the course of leprosy infection. Because of the immune response, rapid spontaneous killing of Mycobacterium leprae occurs once M. leprae have multiplied to the plateau level in immunologically intact (normal) mice; therefore, we concluded that established infection of normal mice is not a convenient system in which to compare the activities of different drug regimens (1). On the other hand, established infection is not the only system in which to study experimental chemotherapy, and we certainly did not intend to imply that other systems could not provide highly predictable results of drug activity in humans. Furthermore, because, to the best of our knowledge, none of the current immunological parameters is well correlated with the antimicrobial activity of a drug against M. leprae, we believe that the immunological parameters are irrelevant to the measurement of antimicrobial activity of the drug in a clinical trial, this despite our full awareness of the important impact of the immune responses of the host on the disease.

Another example of misunderstanding is given in paragraph 4, concerning the requirement of establishing the drug susceptibility status of the organisms before treatment. As described in our paper, because the evidence of the antimicrobial activity of the tested drugs has already been firmly established before conducting a clinical trial, and to exclude the patients who are harboring organisms resistant to these drugs, the pretreatment drug susceptibility status of the organisms should be tested. Although it is absolutely correct that the treatment of leprosy is “more than just antimicrobial activity,” one must nevertheless measure the antimicrobial activity of regimens to be employed. As described in the title of our paper, because the evidence of the antimicrobial activity of the tested drugs has already been firmly established before conducting a clinical trial, and to exclude the patients who are harboring organisms resistant to these drugs, the pretreatment drug susceptibility status of the organisms should be tested. Although it is absolutely correct that the treatment of leprosy is “more than just antimicrobial activity,” one must nevertheless measure the antimicrobial activity of regimens to be employed. As described in the title of our paper, the aim of the controlled clinical trial is to compare the effectiveness of various drug regimens against M. leprae.

We have never underestimated the importance of field trials in the development of new combined regimens as suggested in
paragraph 5 of Dr. Chatterjee's comments. However, we do not accept his opinion that "a field study can substitute for a hospital-based trial." In our view, both clinical (or hospital-based) trials and field trials are interlinked but are not interchangeable. In developing new combined regimens, one must begin somewhere; determining the comparative effectiveness of various drug regimens through controlled clinical trials seems to be the most rational and feasible starting point.

With respect to paragraphs 6 and 7 of Dr. Chatterjee's comments, we emphasize that the aim of the clinical trial is to compare the effectiveness of various drug regimens against *M. leprae*. It is beyond argument that the response of organisms to antimicrobials cannot be directly measured in most treated lepromatous or untreated nonlepromatous patients, but only in previously untreated lepromatous patients.

Certainly, more effective regimens should be developed for those patients who have failed to respond properly to the standard multidrug therapy. Nevertheless, the majority of these failures have occurred among paucibacillary patients whose clinical response is unsatisfactory; at the moment, it is not clear that the inadequate response results from insufficient antimicrobial treatment. It is likely that protocols with different approaches (e.g., immunotherapy) and parameters should be developed for studies among these patients.

Although one should not exaggerate the complexity of planning and conducting a controlled clinical trial, the complexity should not be underestimated. In our limited experience, due to various limitations, very few institutes in the world are capable of conducting a controlled clinical trial independently and properly. Multi-institute collaboration probably is the most feasible approach to solve the potential problems, technical and logistic, faced by a trial.

—Jacques H. Grosset, M.D.
Ji Baohong, M.D.
Laboratoire Central de Bactériologie-Virologie
Groupe Hospitalier Pitié-Salpêtrière
74 et 83 Blvd. de l’Hôpital
75651 Paris 13, France

REFERENCES

Relapses in Multibacillary Leprosy

To the Editor:

I wish to offer the following comments on the paper entitled "Rate and Time Distribution of Relapses in Multibacillary Leprosy," by Kurz, et al. published in the INTERNATIONAL JOURNAL OF LEPROSY 57 (3) 1989, 599-606.

In the life table analysis used in the analysis of the data, it is assumed that the probability of undergoing an event is constant. Factors such as initial bacterial load, age, and immunological status of the patient would have certainly influenced the occurrence of the event, in addition to the treatment and its regularity. Because of the rigid selection criteria, large numbers of patients were excluded from the study. It would be interesting to know whether the group excluded had any particular attributes and the extent to which their exclusion has influenced the figures of relapse rates.

Regarding the statement of the authors in the summary, "The results show no evidence that relapses occurring after 3 years of negativity could be reinfections . . .," I failed to find any evidence from the data published in the paper that supports this statement except probably the continuation of treatment after negativity. Nowhere is it mentioned as to whether all the patients who have relapsed were on dapsone (DDS) until the occurrence of the relapse. Certainly there must be some cases where the treatment was stopped. Add to this the possibility of 20% of the cases (as per the authors' own experience) not consuming the drugs. Then so-called relapses from these two groups could as well be reinfections. In addition, from